Table 3. Clinical characteristics of tuberculosis patients with and without urinary tract cancer (n=135 142).
| Developing urinary tract cancer | Urothelial carcinoma n=411 | Renal cell carcinoma n=98 | No n=134 633 | P-value |
|---|---|---|---|---|
| Age (year) |
69.8±10.6 |
64.7±12.6 |
57.1±19.6 |
<0.001a |
| Male |
327 (79.6%) |
81 (82.7%) |
92 481 (68.7%) |
<0.001b |
| Urinary tuberculosis |
15 (3.6%) |
2 (2.0%) |
1270 (0.9%) |
<0.001b |
| Follow-up duration (year) |
4.6±2.7 |
5.1±3.1 |
7.1±3.2 |
<0.001a |
| Diabetes mellitus |
116 (28.2%) |
29 (29.6%) |
30 339 (22.5%) |
0.006b |
| Obstructive uropathy |
92 (22.4%) |
23 (23.5%) |
18 955 (14.1%) |
<0.001b |
| Urinary tract infection |
41 (10.0%) |
9 (9.2%) |
8719 (6.5%) |
0.002b |
| COPD |
83 (20.2%) |
15 (15.3%) |
19 138 (14.2%) |
0.002b |
| Malignancy |
17 (4.1%) |
4 (4.1%) |
4650 (3.5%) |
0.709b |
| End-stage renal disease |
29 (7.1%) |
6 (6.1%) |
1524 (1.1%) |
<0.001b |
| Autoimmune disease |
4 (1.0%) |
0 |
983 (0.7%) |
0.590b |
| Liver cirrhosis |
1 (0.2%) |
0 |
273 (0.2%) |
0.890b |
| Organ transplantation |
3 (0.7%) |
0 |
122 (0.1%) |
<0.001b |
| Acquired immuno-deficiency syndrome |
0 |
0 |
195 (0.2%) |
0.691b |
| Arsenic intoxication |
1 (0.2%) |
0 |
26 (0.0%) |
0.006b |
|
No. of days in first 2 months of anti-tuberculosis treatment | ||||
| Receiving no anti-tuberculosis agents | 3.7±7.0 | 3.0±6.0 | 3.5±7.0 | 0.672a |
| Receiving ⩾3 anti-tuberculosis agents |
47.5±13.7 |
46.2±14.5 |
48.6±12.6 |
0.034a |
| Complete treatment with standard regimen | 284 (69.1%) | 62 (63.3%) | 96 742 (71.9%) | 0.078b |
Abbreviation: COPD=chronic obstructive pulmonary disease.
a
Calculated by independent-sample Student's t-test
b
Calculated by χ2-square test.
Data were either number (%) or mean±s.d.